1 / 6

PROactive: Study design

PROactive: Study design. Objective: Assess the effects of pioglitazone on reducing macrovascular events in type 2 diabetes Design: Randomized, double-blind, placebo-controlled Population: N = 5238 with type 2 diabetes and history of macrovascular disease

tarak
Télécharger la présentation

PROactive: Study design

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PROactive: Study design Objective: Assess the effects of pioglitazone on reducing macrovascular events in type 2 diabetes Design: Randomized, double-blind, placebo-controlled Population: N = 5238 with type 2 diabetes and history of macrovascular disease Treatment: Pioglitazone (up to 45 mg) or placebo Primary outcome: Composite of all-cause mortality, MI, ACS, coronary or peripheral revascularization, amputation, stroke Secondary outcomes: Individual components of primary outcome, CV mortality Follow-up:4 years Dormandy JA et al. Lancet. 2005;366:1279-89. Charbonnel B et al. Diabetes Care. 2004;27:1647-53.

  2. PROactive: Baseline characteristics Patient description Mean ± SD Age (yrs) 61.8 ± 7.7 Male (%) 66.1 Caucasian (%) 98.5 Type 2 diabetes (yrs since onset) 9.5 ± 7.0 Weight (lbs) 194 ± 34 BMI (kg/m2) 30.9 ± 4.8 Waist circumference (in) 41.46 ± 4.7 Systolic BP (mm Hg) 143.4 ± 17.8 Triglycerides (mg/dL) 198.4 ± 158.8 HDL-C (mg/dL) 44.9 ± 12 LDL-C (mg/dL) 114.5 ± 37 A1C (%) 8.08 ± 1.41 Charbonnel B et al. Diabetes Care. 2004;27:1647-53.

  3. PROactive: CV medications at study entry Current therapy n (%) -Blockers 2859 (55%) ACEI 3286 (63%) ARB 356 (7%) CCB 1855 (35%) Nitrates 2058 (39%) Thiazide 830 (16%) Antiplatelets 4394 (84%) Aspirin 3829 (73%) Statins 2135 (41%) Fibrates 448 (9%) Charbonnel B et al. Diabetes Care. 2004;27:1647-53.

  4. PROactive: Reduction in primary outcome All-cause mortality, nonfatal MI (including silent MI), ACS, revascularization, leg amputation, stroke 25 10% RRR HR* 0.90 (0.80–1.02)P = 0.095 Placebo(572 events) 20 Pioglitazone(514 events) 15 Proportionof events(%) 10 5 0 0 6 12 18 24 30 36 Time from randomization (months) Number at risk Pioglitazone 2488 2373 2302 2218 2146 348 Placebo 2530 2413 2317 2215 2122 345 *Unadjusted Dormandy JA et al. Lancet. 2005;366:1279-89.

  5. PROactive: Reduction in secondary outcome Combined nonfatal MI, all-cause mortality, stroke 25 20 Placebo(358 events) 16% RRR HR* 0.84 (0.72–0.98)P = 0.027 15 Proportionof events(%) 10 Pioglitazone(301 events) 5 0 0 6 12 18 24 30 36 Time from randomization (months) Number at risk Pioglitazone 2536 2487 2435 2381 2336 396 Placebo 2566 2504 2442 2371 2315 390 *Unadjusted Dormandy JA et al. Lancet. 2005;366:1279-89.

  6. PROactive: Reduced need for insulin 25 Placebo(362 events) 20 53% RRR HR* 0.47 (0.39–0.56)P < 0.0001 15 Proportionof events(%) 10 Pioglitazone(183 events) 5 0 0 6 12 18 24 30 36 Time from randomization (months) Number at risk Pioglitazone 1700 1654 1603 1554 1499 244 Placebo 1646 1544 1472 1401 1325 202 *Unadjusted Dormandy JA et al. Lancet. 2005;366:1279-89.

More Related